www.klinickafarmakologie.cz / Klin Farmakol Farm 2023;37(1):5-9 / KLINICKÁ FARMAKOLOGIE A FARMACIE 9 HLAVNÍ TÉMA Současné trendy ve farmakoterapii erektilní dysfunkce 14. Curran M, et al. Tadalafil. Drugs. 2003;63:2203. 15. Bella AJ, et al. Tadalafil in the treatment of erectile dysfunction. Curr Urol Rep. 2003;4:472. 16. Zhou Z, et al. Meta-Analysis of the Long-Term Efficacy and Tolerance of Tadalafil Daily Compared With Tadalafil On- -Demand in Treating Men With Erectile Dysfunction. Sexual medicine. 2019;7:282. 17. Paduch DA, et al. Effects of 12 weeks of tadalafil treatment on ejaculatory and orgasmic dysfunction and sexual satisfaction in patients with mild to severe erectile dysfunction: integrated analysis of 17 placebo-controlled studies. BJU Int. 2013;111:334. 18. Gacci M, et al. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol. 2016;70:124. 19. Keating GM, et al. Vardenafil: a review of its use in erectile dysfunction. Drugs. 2003;63:2673. 20. Capogrosso P, et al. Time of onset of vardenafil orodispersible tablet in a real-life setting – looking beyond randomized clinical trials. Expert Rev Clin Pharmacol. 2017;10:339. 21. Chung E, et al. A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases. Expert Opin Pharmacother. 2011;12:1341. 22. Wang R, et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med. 2012;9:2122. 23. Goldstein I, et al. A randomized, double-blind, placebo- -controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012;9:1122. 24. Corona G, et al. The safety and efficacy of Avanafil, a new 2 generation PDE5i: Comprehensive review and meta-analysis. Expert Opinion on Drug Safety. 2016;15:237. 25. Zámečník L. Moderní léčba poruch erekce – co víme po dvaceti letech. Kapitoly z kardiologie pro praktické lékaře. 2018;10(1):24-27. ISSN 1803-7542. 26. Bittner L. Manažersky dokonalá erekce. Acta Medicinae. 2016;5(11):70. ISSN 1805-398X. 27. Nehra A, et al. Doporučení Princeton III Consensus pro léčbu erektilní dysfunkce a kardiovaskulárních onemocnění. Mayo Clin Proc. 2012;87:766. 28. Vlachopoulos C, a kol. Erektilní dysfunkce u kardiovaskulárního pacienta. Eur Heart J. 2013;34:2034. 29. Corona G, et al. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest. 2008;31:799. 30. Porst H, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10:130. 31. Cai T, et al. The intra-meatal application of alprostadil cream (Vitaros®) improves drug efficacy and patient’s satisfaction: results from a randomized, two-administration route, cross-over clinical trial. Int J Impot Res. 2019;31:119. 32. Kloner RA. Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. Clin Cardiol. 2004;27:I20. 33. Padma-Nathan H, et al. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology. 2006;68:386. 34. Shabsigh R, et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology. 2000;55:109. 35. Eardley I, et al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010;7.524. 36. Moriel EZ, et al. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction. J Urol. 1993;149:1299. 37. Duncan C, et al. Erectile dysfunction: a global review of intracavernosal injectables. World J Urol. 2019;37:1007.
RkJQdWJsaXNoZXIy NDA4Mjc=